Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-028001

CHIEF FINANCIAL OFFICER sold 5,250 shares at an average $24.89 ($130,688)

  • CHIEF FINANCIAL OFFICER acquired 5,250 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hohl Benjamin · CHIEF FINANCIAL OFFICER

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2024-11-27 Exercise or conversion : show line 1 in the form 10b5-1 +5,250 $2.48 $13,020 5,250 D
2024-11-27 Sale : show line 2 in the form 10b5-1 −4,250 $24.78 $105,313 1,000 D
2024-11-27 Sale : show line 3 in the form 10b5-1 −1,000 $25.38 $25,376 0 D
Open-market sales · 5,250 sh · avg $24.89 · $130,688

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-11-27 Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (right to buy) −5,250 168,556 D
Loading xslF345X05/form4-12022024_101235.xml…